What we think about Mirati Therapeutics, Inc. (NASDAQ: MRTX) Pay

0
89

[ad_1]

<p class = "Canvas-Atom Canvas-Text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Charles Baum was the CEO of Mirati Therapeutics, Inc. (NASDAQ: MRTX) since 2012. This report first examines the amount of CEO compensation compared to CEO compensation for companies of similar size. After that, we will take into account the growth of the business. Third, we will consider total shareholder return over a three year period as a second measure of business development. This process should give us an idea of ​​how fairly the CEO is being paid. "Data-reactid =" 27 "> Charles Baum has been CEO of Mirati Therapeutics, Inc. (NASDAQ: MRTX) since 2012. This report will first examine the level of CEO compensation compared to CEO compensation for companies of similar size. Then we will look at the growth of the business, and third, we will consider the total return for shareholders over three years as the second business size. This process is to give us an idea of ​​how fairly the CEO is being paid.

<p class = "canvas-atom canvas-text Mb (1,0em) Mb (0) – sm Mt (0,8em) – sm" type = "text" content = " Check out our latest analysis for Mirati Therapeutics "data-reactid =" 28 "> Check out our latest analysis for Mirati Therapeutics

How does Charles Baum's compensation compare to comparable companies?

According to our data, Mirati Therapeutics, Inc. is valued at $ 4.6 billion and the CEO's total annual compensation was $ 4.9 million for the year ended December 2018. Although we always look at total compensation first, we find that the salary component is lower, at $ 580,000. We find that more than half of the total compensation is not the salary; and performance requirements may apply to this non-salary portion. As part of our analysis, we examined companies in the same legal system with market capitalizations of USD 2.0 to 6.4 billion. The average total CEO compensation was $ 5.1 million.

So Charles Baum is paid on average for the companies we looked at. While this data point is not particularly informative, it is becoming more important in terms of business performance.

Below is a visual representation of CEO compensation at Mirati Therapeutics.

NasdaqGS: MRTX CEO Compensation, January 3, 2020

Is Mirati Therapeutics, Inc. Growing?

Mirati Therapeutics, Inc. has reduced earnings per share by an average of 1.8% per year over the past three years (as measured by the Best Fit line). Sales decreased 34% last year.

<p class = "Canvas-Atom Canvas-Text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "In the past three years the company has not done this Earnings per share are increasing, and the fact that sales are down year-on-year gives an ugly picture, and it's hard to say the company is firing on all cylinders, so shareholders may be reluctant to pay the CEO a lot This free visual representation of what analysts expect for the future, "data-reactid =" 47 "> The company has failed to increase earnings per share over the past three years. The fact that sales have declined compared to the previous year paints a bad picture. Shareholders may be against one high compensation from the CEO. It may be important to review this free visual representation what analysts expect for the future.

Was Mirati Therapeutics, Inc. a good investment?

Most shareholders would likely enjoy a 1939% total return over three years from Mirati Therapeutics, Inc. This strong performance could mean that some shareholders don't mind if the CEO receives higher compensation than is customary for a company of this size.

In total…

Charles Baum, like most CEOs, is paid by companies of similar size.

<p class = "canvas-atom-canvas-text Mb (1,0em) Mb (0) – sm Mt (0,8em) – sm" type = "text" content = "We believe that the result is ever Shares have been disappointing, but it's nice to see that positive stock returns have been achieved over the past three years, so we believe that most shareholders would not be too concerned about the remuneration of CEOs who are close to the median for companies of similar size Check to see if Insider is buying or selling Mirati Therapeutics stock (free trial)."data-reactid =" 52 "> We believe earnings per share have been a little disappointing, but it's nice that shareholders have seen positive returns over the past three years, regardless of how they rate the compensation you should check to see if Insider is buying or selling Mirati Therapeutics stock (free trial).

<p class = "Canvas-Atom Canvas-Text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "If you want to buy a stock that is better than Mirati Therapeutics, this free List of high return, low debt companies is a great place to search."data-reactid =" 53 "> If you want to buy a stock that is better than Mirati Therapeutics, this is the case free List of high return, low debt companies is a great place to search.

<p class = "canvas-atom canvas-text Mb (1,0em) Mb (0) – sm Mt (0,8em) – sm" type = "text" content = "If you discover an error that justifies a correction, please contact the editorial team at editorial-team@simplywallst.com, This article from Simply Wall St is general in nature. It is not a recommendation to buy or sell shares and does not take into account your goals or your financial situation. Simply Wall St has no position in the stocks mentioned.

We strive to provide you with long-term, focused research analysis based on fundamental data. Note that our analysis may not take into account the latest price-sensitive company announcements or quality material. Thank you for reading."data-reactid =" 54 ">If you discover an error that justifies a correction, please contact the editorial team at editorial-team@simplywallst.com. This article from Simply Wall St is general in nature. It is not a recommendation to buy or sell shares and does not take into account your goals or your financial situation. Simply Wall St has no position in the stocks mentioned.

We strive to provide you with long-term, focused research analysis based on fundamental data. Note that our analysis may not take into account the latest price-sensitive company announcements or quality material. Thank you for reading.